There is no question in our mind that over the next 18 to 24 months we are going to see some major advancements for insulin using patients. Thanks to Dexcom and Abbott CGM technology has become not just more patient friendly but also more patient accessible. Thanks to Medtronic and Tandem insulin pump technology is advancing ever closer to a true closed loop insulin delivery system. Thanks to TypeZero and others insulin dosing algorithms will go beyond insulin pumps and extend to patients who use “smart”insulin pens.
Although we would never claim that insulin therapy is easy with these . . .
This content is restricted to subscribers. Please subscribe.
Already have an account? Please login.